Nearly 100,000 people in Sweden suffer from Alzheimer’s. Globally, about 30 million people are thought to have the disease. There is still no cure, but research is approaching a point where new drugs may become crucial. AlzeCure is one of the pharmaceutical companies that has made the most progress.
During the course of the pandemic, he has appeared on an almost daily basis in the morning papers or on the TV news. Matti Sällberg fast became an expert the media called for help explaining everything from vaccine development to the spread of infection.
After 10 years as a start-up, CellProtect Nordic Pharmaceuticals has taken a major step forward. Our patient and careful work is now bearing fruit, explains Karin Mellström, CEO and founder. Looking back on her career, she sums it up by saying: “I’d never been bored for a second!”
A recent study could pave the way to treating a type of bone marrow cancer. The aim is to transform the cancer from being incurable to a disease that it is possible to live with. The research behind the study was conducted in Evren Alici’s group at Campus Flemingsberg.
Mathias Svahn is a CEO who still collects the mail and makes the coffee, even as he ranks among the highflyers leading the development of drugs of the future. Curiosity has taken him from the lab to the helm of a listed company. And it all started with a pregnancy.
Chris Heister: “Everyone who has made this journey feels as though they’re fighting the system a bit.”
Even if Chris Heister shifts down a gear when she leaves her role as council leader in Stockholm, she is unlikely be drawing on her pension any time soon. The class journey she has made from growing up in a countryside idyll, north of Stockholm, has given her a momentum that continually drives her forward.
After almost 25 years’ concerted struggle to disseminate her successful eating disorder treatment, Cecilia Bergh wants to shift up a gear. Her goal is to digitalise her technique and turn the Mandometer support tool into a consumer product.
Pontus Blomberg has guided the development of Vecura in Flemingsberg for more than 20 years. Here, together with his colleagues, he has built up Sweden’s leading gene and cell therapy lab. An area that is set to lead to remedial treatments for everything from certain cancers to Alzheimer’s.
Vesna Jovic is now leaving her role as municipality director for Huddinge – after 28 years at the authority. Her next position is CEO for the Swedish Association of Local Authorities and Regions, SKL. As she leaves Huddinge, she can look back on the burgeoning development of Flemingsberg and Huddinge.